| Revenue growth | FY26 up 12.5%; US up 24%; Australia Q4 up 61.3%. |
|---|---|
| Margins | FY26 gross margin 56.7%; EBITDA 20.4%. Margins expected stable. |
| Demand visibility | Strong momentum in US and recovery in UK trajectory. |
| Management confidence | High; aiming to double revenue in 3-5 years. |
Growth
FY26 revenue grew 12.5% to ₹2,951cr; PAT reached ₹420cr; Q4 EBITDA margin expanded 491 bps to 22.8%.
Outlook
Guided ₹4,000cr revenue by FY28; target 15-20% growth for FY27. Active due diligence on two M&A targets.
Risks
Near-term raw material inflation due to geopolitical/supply chain issues and competitive pricing pressure in US markets.
Earnings Call filed with BSE, NSE: MARKSANS. Summary written with AI assistance from the document.
Marksans Pharma Ltd: key numbers
- Share price
- ₹325.45
- Market cap
- ₹14,748 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 28.5×Sector 47.3×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 17.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Promoter Selling (Off-Market)
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma Other Announcement
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.
Marksans Pharma Annual General Meeting
Marksans Pharma Limited conducted its 34th Annual General Meeting on August 27, 2026. Shareholders considered the adoption of FY2025-26 financial statements and a dividend of Rs. 0.90 per share.
Marksans Pharma Other Announcement
Marksans Pharma Ltd. has received an ESG score of 56 from Crisil ESG Ratings & Analytics Ltd for Fiscal 2026.
Marksans Pharma Investor Presentation: Key Takeaways
Strong Q1FY27 performance driven by European growth and acquisitions. Marksans achieved highest-ever quarterly EBITDA and PAT, while crossing INR1,000 Cr cash balance.
- Call
- Guides 20% growth
Marksans Pharma Q1 FY27 Results: Net Profit ₹159.4 Cr, Up 173.9% YoY
Marksans Pharma Ltd reported revenue from operations of ₹840.8 Cr (+35.6% YoY) and net profit of ₹159.4 Cr (+173.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹159.4 Cr · +173.9% YoY